Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Trevena, Inc. (TRVN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.4800-0.0274 (-5.40%)
At close: 04:00PM EST
0.5298 +0.05 (+10.38%)
After hours: 06:06PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.5074
Open0.5462
Bid0.4900 x 1000
Ask0.5299 x 1000
Day's Range0.4630 - 0.5590
52 Week Range0.4630 - 3.1000
Volume1,348,431
Avg. Volume1,498,143
Market Cap78.969M
Beta (5Y Monthly)2.17
PE Ratio (TTM)N/A
EPS (TTM)-0.3060
Earnings DateMar 07, 2022 - Mar 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.67
  • GlobeNewswire

    Trevena Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical

    Submission supported by data from a Phase 3 bridging study of oliceridine injection compared to IV morphine, conducted in China by Nhwa Trevena is eligible to receive future success payments upon approval and commercialization milestones, as well as a 10% royalty on net sales in China CHESTERBROOK, Pa., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous s

  • GlobeNewswire

    Trevena to Participate in the Upcoming January Conferences

    CHESTERBROOK, Pa., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President & CEO and Barry Shin, Chief Financial Officer, will be participating in three January virtual investor and partnering conferences, with additional details below. Conference Details LifeSci Partners - 11th Annual Corp

  • Zacks

    Trevena (TRVN) to Begin Clinical Study on Pain Candidate

    Trevena (TRVN) advances TRV045 into clinical development as a potential treatment for diabetic neuropathic pain. Enrollment in the study is expected to begin in the first quarter of 2022.

Advertisement
Advertisement